Lead Development and Optimization Shared Resource

销售线索开发和优化共享资源 铅开发和优化（LDO）共享资源是KUCC的一个使命关键要素，使我们能够重新定义学术癌症中心的转化研究。它是癌症中心战略的一个关键组成部分，通过传统的先导化合物开发和优化或药物再利用策略，优化基础研究成果快速转化为新的治疗进展。LDO通过以下方式促进转化研究：1）为从事癌症治疗和预防新疗法发现和开发的研究人员和临床医生提供支持，2）为KUCC转化研究项目提供药物发现，交付和开发专业知识，以及3）支持与工业，学术，政府和疾病慈善组织，我们与他们建立了合作关系，以支持我们的目标和主题， 科学研究计划。 LDO由Michael J. Baltezor博士指导，是一种多组分共享资源，提供了药物发现，交付和开发方面的独特专业知识和能力，这在学术环境中很少提供。通过将训练有素、行业经验丰富的科学家和最先进的设备相结合，LDO能够支持以下临床前领域的新型癌症治疗方法的开发： 1)药物发现高通量筛选（HTS）-研究和开发重点是高通量方法开发和化合物探针筛选的靶点选择和验证; 2)药物递送生物技术创新和优化设施（BIOF）-研究和 开发重点是常规和新型药物输送和动物药代动力学支持; 3)临床前概念验证（PPOC）-体外铅优化和开发新的和改进的癌症动物模型，以测试具有在啮齿动物中进行整体动物成像能力的铅分子。 LDO在2010年为51个研究项目提供了支持，其中32个（62%）由KUCC成员领导。在过去的三年里，LDO帮助KUCC研究人员将五种药物疗法推进到I期临床试验，并以具有成本效益和效率的方式进行。总体而言，癌症中心成员与同行评审的研究资金使用了约75%的LDO的能力。

Lead Development and Optimization Shared Resource The Lead Development and Optimization (LDO) shared resource is a mission critical element of KUCC that allows us to redefine translational research in an academic cancer center. It is a key component of the Cancer Center's strategy to optimize the rapid movement of basic research findings into new therapeutic advances either through traditional lead compound development and optimization, or drug repurposing strategies. The LDO fosters translational research by: 1) providing support to researchers and clinicians engaged in the discovery and development of novel therapeutics for treatment and prevention of cancer, 2) providing drug discovery, delivery and development expertise to KUCC translational research projects, and 3) supporting key collaborations with industry, academic, government and disease philanthropy organizations with whom we have established collaborations in support of the goals and themes of our scientific research programs. The LDO, directed by Michael J. Baltezor, PhD, is a multi-component shared resource that provides unique expertise and capabilities in drug discovery, delivery, and development that is rarely available in an academic setting. Through a combination of highly trained, industry-experienced scientists and state-of the- art equipment the LDO is capable of supporting the development of novel cancer therapeutics in the following preclinical spaces: 1) Drug Discovery High Throughput Screening (HTS) - research and development focused on target selection and validation for high throughput method development and compound probe screening; 2) Drug Delivery Biotechnology Innovation and Optimization Facility (BIOF) - research and development focused on conventional and novel drug delivery and animal pharmacokinetic support; 3) Preclinical Proof of Concept (PPOC) - in vitro lead optimization and development of new and improved animal models for cancer to test lead molecules with capabilities to perform whole animal imaging in rodents. The LDO provided support for 51 research projects in 2010, 32 (62%) were led by KUCC members. During the past three years the LDO was instrumental in helping advance five drug therapies by KUCC investigators into Phase I clinical trials and to do so in a cost effective and efficient manner. Overall, Cancer Center members with peer-reviewed research funding used approximately 75% of the LDO's capacity.